(The) development status of PET radiotracers for evaluating neuroinflammation
|
Namhun Lee, Jae Yong Choi, Young Hoon Ryu
|
p. 160-176
|
|
|
|
(A) key mediator and imaging target in Alzheimer’s disease : unlocking the role of reactive astrogliosis through MAOB
|
Min-Ho Nam, Heesu Na, C. Justin Lee, Mijin Yun
|
p. 177-184
|
|
|
|
Imaging procedure and clinical studies of [18F]FP-CIT PET
|
Changhwan Sung, Seung Jun Oh, Jae Seung Kim
|
p. 185-202
|
|
|
|
(A) review of machine learning approaches for brain positron emission tomography data analysis
|
Ke Xu, Hakmook Kang
|
p. 203-212
|
|
|
|
Radionuclide imaging of the neuroanatomical and neurochemical substrate of cognitive decline in Parkinson’s disease
|
Samuel Booth, Ji Hyun Ko
|
p. 213-226
|
|
|
|
Anti-amyloid antibody therapies for Alzheimer’s disease
|
Kyung Won Park
|
p. 227-236
|
|
|
|
Recent update on PET/CT radiotracers for imaging cerebral glioma
|
Dongwoo Kim, SukHyun Lee, Hee Sung Hwang, Sun Jung Kim, Mijin Yun
|
p. 237-245
|
|
|
|
Clinical performance evaluation of an artificial intelligence-powered amyloid brain PET quantification method
|
Seung Kwan Kang, Mina Heo, Ji Yeon Chung, Daewoon Kim, Seong A. Shin, Hongyoon Choi, Ari Chung, JungMin Ha, Hoowon Kim, Jae Sung Lee
|
p. 246-254
|
|
|
|